HEE-GER: a systematic review of German economic evaluations of health care published 1990–2004 by Schwappach, David LB & Boluarte, Till A
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Health Services Research
Open Access Correspondence
HEE-GER: a systematic review of German economic evaluations of 
health care published 1990–2004
David LB Schwappach*1,2 and Till A Boluarte2
Address: 1Research Institute for Public Health and Addiction, Konradrstrasse 32, 8031 Zurich, Switzerland and 2Health Policy, Faculty of Medicine, 
University Witten-Herdecke, Alfred-Herrhausen-Str. 50, 58448 Witten, Germany
Email: David LB Schwappach* - David.Schwappach@isgf.unizh.ch; Till A Boluarte - Till.Boluarte@uni-wh.de
* Corresponding author    
Abstract
Background: Studies published in non-English languages are systematically missing in
systematic reviews of growth and quality of economic evaluations of health care. The
aims of this study were: to characterize German evaluations, published in English or
German-language, in terms of various key parameters; to investigate methods to derive
quality-of-life weights in cost-utility studies; and to examine changes in study
characteristics over the years.
Methods: We conducted a country-specific systematic review of the German and
English-language literature of German economic evaluations (assessment of or
application to the German health care system) published 1990–2004. Generic and
specialized health economic databases were searched. Two independent reviewers
verified fulfillment of inclusion criteria and extracted study characteristics.
Results: The fulltexts of 730 articles were reviewed of which 283 fulfilled all entry
criteria. 32% of included studies were published in German-language. 51% of studies
evaluated pharmaceuticals and 63% were cost-effectiveness analyses. Economic
appraisals concentrate on few disease categories and important health areas are
strongly underrepresented. Declaration of sponsorship was associated with article
language (49% English articles vs. 29% German articles, p < 0.001). The methodology
used to obtain quality-of-life weights in published cost-utility studies was very diverse,
poorly reported and most studies did not use German patients' or community health
state valuations.
Conclusion: Many of the German-language evaluations included in our study are likely
to be missing in international reviews and may be systematically different from English-
language reviews from Germany. Lack of transparency and adherence to recommended
reporting practices constitute a serious problem in German economic evaluations.
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Background
Economic evaluation of health care has evolved as an
important tool for assessing the costs and benefits of
health care and a large amount of evaluation studies has
been published during the last decades. Several systematic
reviews have been conducted that assessed the character-
istics and quality of published studies [1-4]. The main
conclusions that can be drawn from these studies is that
adherence to methodological standards is increasing but
still far from perfect. For example, in an analysis of phar-
macoeconomic submissions to the Australian Pharmaceu-
tical Benefits Scheme, 67% of submissions had significant
problems [5]. The majority of problems identified (64%)
were deemed avoidable. Neuman et al. report in an anal-
ysis of cost-utility studies that in only 73% of the studies
published 1998–2001, the authors clearly presented the
study perspective [1]. In a recent analysis of cost data in
economic evaluations conducted alongside randomized
controlled trials, only 37% of the reviewed evaluations
presented a cost-effectiveness ratio or estimated net bene-
fits and only 57% of these reported the uncertainty of this
statistic [6]. However, these reviews have covered the Eng-
lish-language literature only, and analyses published in
languages other than English are therefore systematically
missing. However, as evaluation studies are highly context
dependent, it is likely that many studies are being pub-
lished in the languages of the countries whose health care
systems have been addressed. These country-specific anal-
yses, often published in national journals, may also have
considerable impact on local decision makers. Until now,
no systematic review has been conducted to assess growth,
characteristics and quality of German economic evalua-
tions. The aim of this study was to overcome this gap and
to 1) analyze in which journals and in which language
German economic evaluations have been published; 2)
describe the characteristics of the studies in terms of vari-
ous key parameters, such as type of evaluation, study
design, covered diseases, study perspective, funding
sources and others; 3) examine changes in study and pub-
lication characteristics over the years and 4) investigate
methods to derive quality-of-life weights in cost-utility.
While our study included all types of full economic eval-
uations, we paid special attention to cost-utility-analyses,
the methods used to derive utilities for calculation of
quality-adjusted life years (QALYs) in published studies
and, in particular, whether preferences have been elicited
from German patients or community members.
Methods
Literature search and study selection
We searched the databases Embase, Pubmed, Econlit (sil-
verplatter), Cinahl, NHS-Pharmline, NHS EED, and OHE
HEED for relevant articles. The searches were conducted
in April 2005. In addition, the references of retrieved arti-
cles were manually searched for further material. The rel-
evant volumes of a German-language health economic
journal were completely hand searched for relevant arti-
cles as this journal is not systematically covered in inter-
national databases [7]. We also contacted a list of German
health economists and recognized authors (n = 63) via
email and asked to provide us their bibliographic data. Of
those, 17 (27%) responded and sent their publication
record and relevant material. As the use or translation of
technical terms for indexing non-English literature in
international databases is often inconsistent or errant we
defined a search strategy with high sensitivity but low spe-
cificity [8,9]. The search strategy consisted of freetext and
MeSH terms related to economic evaluation. The resulting
hits were filtered for the occurrence of the terms "Ger-
man" or "Germany" in any field. The retrieved records
were further refined for the relevant year range and, where
available, limited to journal articles. The search strings are
provided in the Appendix (see Additional file 1). Studies
were included in the review when they fulfilled all of the
following inclusion criteria:
• Full economic evaluation, i.e., comparative analysis of
costs and outcomes of at least two alternatives;
• Applied study (trial generating primary data or mode-
ling of secondary data). Reviews, letters, abstracts, meth-
odological and general articles were excluded;
• Assessment of or application to the German health care
system;
• Journal articles, i.e., exclusion of books, HTA reports,
grey literature;
• Published between 1990–2004 (i.e., after German
reunification);
• Published in English or German-language
We did limit our analysis to evaluations published in offi-
cial journals to assess those publications that have at least
undergone some basic quality control. While, for exam-
ple, some newer Health Technology Assessment reports
may report original data analysis and would have there-
fore fitted our inclusion criteria in principle, they are usu-
ally not subject to external standardized peer review. It is
also often hard to define what constitutes a HTA report
since they may be published as grey literature by non-offi-
cial agencies.
Data extraction and critical appraisal
We developed a checklist comparable to that used by
other researchers to extract data from the fulltexts along-
side review [1,10]. We collected details on study objective,
intervention type and disease category, design, methodol-BMC Health Services Research 2007, 7:7 http://www.biomedcentral.com/1472-6963/7/7
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ogy and background data such as sponsorship. The data
extraction form did not include explicit quality ratings. As
one of our interests was the investigation of health effects
assessment in cost-utility studies, data relating to health
and preference measurement methodology were extracted
in detail. We recorded the health measurement instru-
ment used, the technique used for valuing health states,
and the groups of individuals from whom quality of life
data and valuations were obtained. We also compared the
extracted data relating to utility measurement and report-
ing of QALY calculation against criteria recommended by
Stalmeier et al. [11] and Richardson and Manca [10].
These criteria include, e.g., reporting of elicitation proce-
dure, sample size, anchor states, and others. For all stud-
ies, we used only the information provided in the original
publication. However, in case the published methodology
regarding health status measurement provided in cost-
utility studies was not sufficiently detailed to extract the
data as needed but authors referred to other studies as
data source, these references were obtained to extract the
relevant information. For example, if authors cited a sec-
ond study as source for utilities, we obtained this article to
determine whether this study contained information on
utility elicitation. Each paper was independently read by a
single researcher. A random sample of 10% of studies was
assessed by two reviewers to determine interrater reliabil-
ity for each item. Cost-utility studies were all reviewed by
both reviewers. Reviewers were also allowed to defer stud-
ies in case they were uncertain about one or more items.
These studies were assessed by a second reviewer and dis-
cussed in consensus meetings to resolve discrepancies.
After critical appraisal, information collected in data
extraction forms were transferred to an electronic data-
base.
Analysis of data
Kappa statistics (K) were calculated to assess interrater
reliability for each item. We analyzed the distribution of
extracted categories of economic evaluations and investi-
gated differences between journal specialty (medical vs.
health care sciences journals, as defined by the ISI Journal
Citation Reports subject category listing) and German and
English-language articles. To assess developments over
time, we defined the year ranges 1990–1998 and 1999–
2004. Comparisons were made using chi-square tests. A p-
value of less than 0.05 was considered significant. All
analyses were performed using STATA 9 software [12].
Results
The systematic literature search initially identified 2,158
candidate articles, of which 724 were selected for fulltext
retrieval (figure 1). The majority of articles were discarded
at this initial stage mainly because they were duplicates, or
it was obvious from the bibliographic data that they vio-
lated basic inclusion criteria. Further 9 articles were iden-
tified through hand searching or submitted by the
contacted experts. 3 articles were not available as fulltexts,
neither from the publisher or document suppliers nor
directly from the authors. In summary, the fulltexts of 730
articles were reviewed. 447 articles were dropped after the
critical appraisal because they failed one or more inclu-
sion criteria. Interrater reliability (K) was assessed on a
sample of 90 studies (10% random sample + all remain-
ing 17 CUAs not included in this sample by random). K
was 0.978 (95% CI 0.934 – 1.0) for study inclusion, i.e.,
fulfillment of all entry criteria. K for all other items ranged
from 0.921 (95% CI 0.885–1.0) for primary disease cate-
gory to 1.0 for the items 'study design' and 'study setting'.
Overall, a very good level of agreement was observed [13].
283 studies fulfilled all entry criteria.
Basic characteristics of included studies
As can be seen from figure 2, publication of German
health economic studies has steadily increased until 1998
and has since then remained relatively stable with approx-
imately 30 studies published per year. Of the included
studies, 91 (32%) were published in German-language
and no stable trend towards internationalization (in
terms of publication in English-language) could be
observed. The studies concentrate on few journals, and
134 out of 151 journals (89%) published less than three
German economic evaluations between 1990 and 2004
(table 1). The vast majority of studies (79%) was pub-
lished in medical journals in contrast to specialized health
economic or health care sciences journals. The 91 Ger-
man-language articles were published in 39 different Ger-
man journals (37 medical and 2 health economics/
services journals) with a median of 1 evaluation pub-
lished per journal. Only 21 of these journals are listed in
the ISI Journal Citation Reports.
Table 2 reports the characteristics of the included studies.
Of the 283 studies that fulfilled all entry criteria, 0.4%
were cost-benefit analyses, 6% cost-utility analyses, 14%
cost-minimization analyses, 18% cost-effectiveness analy-
ses with "life years gained" as outcome measure and 45%
were cost-effectiveness analyses that used a clinical out-
come as measure of effectiveness. Many studies (17%)
were observational studies with information on costs that
left health outcomes disaggregated and used no summary
measure of benefit (cost consequence analyses). 20% of
studies were multinational studies that evaluated health
care in more than one country (Germany), usually in the
context of other European nations.
Funding sources and disclosure of funding
Figure 3 shows the distribution of funding statements and
different types of sponsorship organizations by year
range. Among those studies that included a clear funding
statement (n = 120) the fraction of industry-sponsoredBMC Health Services Research 2007, 7:7 http://www.biomedcentral.com/1472-6963/7/7
Page 4 of 11
(page number not for citation purposes)
studies is very high (77%) and decreased only slightly
(85% in 1990–1998 vs. 73% in studies published 1999–
2004, p = 0.572). For studies that evaluated pharmaceuti-
cal products, this figure is even higher (91%). Declaration
of sponsorship was strongly associated with journal spe-
cialty (35% medical journal articles disclosing funding vs.
69% articles in health economic journals, p < 0.001) and
with article language (49% of English articles vs. 29% of
German-language articles, p < 0.001). The fraction of Ger-
man-language studies that declared funding increased
from 23% in articles published between 1990 and 1998 to
32% of studies published between 1999 and 2004 (p =
0.340).
Trends in published evaluations
As can been seen from the comparison of studies pub-
lished prior to 1999 and those published between 1999
and 2004, there seems to be a systematic trend towards
more comprehensive methods of evaluation and study
designs. Articles published after 1998 were more likely to
be conducted alongside randomized controlled trials at
the expense of modeling and observational studies (4%
vs. 16%, p = 0.009). We also observe differences in distri-
bution of studies by primary ICD-9 category between the
time periods. While the same five categories remain the
most used ones, a distinct increase in studies evaluating
care relating to nervous system and sense organ diseases
Overview of in- and exclusion of studies Figure 1
Overview of in- and exclusion of studies.
Identified articles
(n=2158)
Excluded due to violation 
of basic inclusion criteria 
(e.g.,duplicates, abstracts)
(n=1434)
Initial inclusion
(n=724)
   + 9 identified by experts, handsearching
   - 3 not available as fulltexts
Fulltext retrieval for
critical appraisal
(n=730)
Dropped after critical appraisal
(n=447), due to
- No full evaluation (n=193)
- No applied study (n=189)
- No German data (n=62)
- Other reasons (n=3)
Included evaluations
(n=283)BMC Health Services Research 2007, 7:7 http://www.biomedcentral.com/1472-6963/7/7
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results in a switch of ranks with the endocrine, nutritional
and metabolic disease category. In addition, the later time
period (1999–2004) is characterized by more diversity in
studied ICD-9 categories as an increase in the "other" cat-
egory documents. This variation may also be related to the
strong increase in the assessment of medical procedures.
Study perspective
In less than half of all studies the authors explicitly
reported the perspective the study was undertaken from,
but this fraction significantly increased over time (41% in
1990–1998 vs. 62% in 1999–2004, p < 0.001). Study per-
spective reporting practice was strongly associated with
journal specialty (35% in medical journals vs. 69% in
health care sciences journals, p < 0.001) and the observed
shift is mainly attributable to changes in reporting prac-
tice in studies published in medical journals during the
last years. However, not only the reporting of study per-
spective has significantly increased but also the distribu-
tion of the different perspectives chosen by investigators.
Considering only those studies that included a clear state-
ment on the chosen perspective (n = 157), the fraction of
studies undertaken from the more comprehensive societal
perspective rose from 11% in the first to 20% in the sec-
ond time period (p = 0.032). Of the 28 studies claimed to
be undertaken from the societal perspective, 18 were cost-
effectiveness studies with clinical measures of effective-
ness, 5 were cost-effectiveness studies with life years
gained as outcome, 4 were cost-utility studies and the
remaining was a cost-minimization study. This distribu-
tion indicates that the societal perspective manifested
itself more frequently in a comprehensive costing meth-
odology rather than in the societal valuation of benefits.
Analysis of cost-utility studies
Among the 18 identified cost-utility-studies, 16 were pub-
lished in medical journals of which 3 articles were in Ger-
man-language and 2 were published in health economic
Included studies by article language and publication year Figure 2
Included studies by article language and publication year.
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Table 2: Characteristics of included studies
1990–1998 (n = 87) 1999–2004 (n = 196) 1990–2004 (n = 283)
No. (%) studies No. (%) studies No. (%) studies
By study type
Cost minimization 16 (18.4) 23 (11.7) 39 (13.8)
Cost consequence 13 (14.9) 34 (17.4) 47 (16.6)
Cost effectiveness (life years gained) 17 (19.5) 35 (17.9) 52 (18.4)
Cost effectiveness (clinical outcome) 38 (43.7) 88 (44.9) 126 (44.5)
Cost utility 3 (3.5) 15 (7.7) 18 (6.4)
Cost benefit 0 (0) 1 (0.5) 1 (0.4)
By study design
Alongside RCT 3 (3.5) 31 (15.8) 34 (12.0)
Modeling study 53 (60.9) 101 (51.5) 154 (54.4)
Combination RCT/Modeling 3 (3.5) 15 (7.7) 18 (6.4)
Observational 28 (32.2) 49 (25.0) 77 (27.2)
By study perspective (as stated by authors)
Not stated 51 (58.6) 75 (38.3) 126 (44.5)
Third party payer (e.g., insurance) 32 (36.8) 83 (42.4) 115 (40.6)
Societal 4 (4.6) 24 (12.2) 28 (9.9)
Other (mainly 'patients')* 0 (0) 14 (7.1) 14 (5.0)
By disease category (ICD-9 category heading)
Circulatory system 22 (25.3) 35 (17.9) 57 (20.1)
Neoplasms 13 (14.9) 23 (11.7) 36 (12.7)
Infectious and parasitic 12 (13.8) 20 (10.2) 32 (11.3)
Nervous system and sense organs 4 (4.6) 20 (10.2) 24 (8.5)
Endocrine, nutritional, metabolic 7 (8.1) 15 (7.7) 22 (7.8)
Other* 29 (33.3) 83 (42.3) 112 (39.6)
By level of care
Curative 63 (72.4) 148 (75.5) 211 (74.6)
Rehabilitative 2 (2.3) 6 (3.1) 8 (2.8)
Preventive 22 (25.3) 42 (21.4) 64 (22.6)
By intervention type
Pharmaceutical 49 (56.3) 96 (49.0) 145 (51.2)
Medical procedure 6 (6.9) 38 (19.4) 44 (15.6)
Screening 12 (13.8) 16 (8.2) 28 (9.9)
Other* 20 (23.0) 46 (23.5) 66 (23.3)
* Summarized over extracted categories
Table 1: Distribution of included articles by journal and journal specialty
1990–1998 (n = 87) 1999–2004 (n = 196) 1990–2004 (n = 283)
No. (%) studies No. (%) studies No. (%) studies
By journal
Pharmacoeconomics (E H) 10 (11.5) 18 (9.2) 28 (9.9)
Medizinische Klinik (G M) 9 (10.3) 6 (3.1) 15 (5.3)
Gesundheitsökonomie & Qual.mgmt (G H) 1 (1.1) 13 (6.6) 14 (4.9)
Deutsche Medizinische Wochensch r i f t  ( G  M ) 1( 1 . 1 )7( 3 . 6 )8( 2 . 9 )
European Heart Journal (E M) 2 (2.3) 5 (2.6) 7 (2.5)
Other (n = 146 journals)* 64 (73.6) 147 (75.0) 211 (74.6)
By journal specialty
Medical journals 70 (80.5) 154 (78.6) 224 (79.2)
Health economics/services journals 17 (19.5) 42 (21.4) 59 (20.9)
* Summarized over extracted categories; (E) English-language journal; (G) German-language; (M) Medical journal; (H) Health economics/services 
journalBMC Health Services Research 2007, 7:7 http://www.biomedcentral.com/1472-6963/7/7
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journals. The methodology used to obtain utilities was
very diverse and generally poorly reported. The vast
majority of studies (n = 13) relied at least to some extent
on secondary data but failed to provide even basic infor-
mation on the methodology used in the secondary
sources. In particular, most studies did not specify the
original populations involved (e.g., sample size, country
of origin, experts, patients or general public) and the rele-
vant information was extracted by consulting the cited
original sources. Four studies obtained primary data on
patients' self-assessed quality-of-life or experts' assess-
ment on behalf of their patients from small samples (n
ranges between 22 patients and 70 experts). Quality-of-
life data were then transformed into utilities using either
disease category mapping to the Rosser-Matrix or empiri-
cally estimated transformations such as the Brazier func-
tion based on other nations' general population values
[14]. Two modeling studies used a published transforma-
tion of disease-specific disability measures to time-trade
off values originally obtained in a Canadian sample [15].
Two analyses referred to original studies that had used
patients' quality-of-life assessment or experts' visual-ana-
logue scale values from Sweden and Netherlands respec-
tively and had applied a transformation or weighting
("social tariff") function based on health-related prefer-
ences from yet another country. Two studies used US-
American values from multiple sources that were based on
empirical analysis or expert judgment. Four studies relied
completely on "judgment" without reference to secondary
data or on published utility values for which it was
unclear even from the original article whether these were
empirically derived or based on judgment.
Four studies were classified as calculating quality-adjusted
life years based on "primary data" of which three were
modeling studies that referred to their quality-of-life data
collection published elsewhere. Two of these articles pub-
lished by the same working group report in their primary
Included studies by funding statement, article language and publication year range Figure 3
Included studies by funding statement, article language and publication year range.
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studies extensive quality-of-life assessment using different
techniques in samples of 348 and 428 German patients.
Utilities used for the base case of the analyses were derived
by using patients' rating scale values and transforming
these into utilities with the "Torrance" function which is
based on preferences elicited via the standard-gamble in a
sample of Canadian citizens [16]. Values obtained by
other elicitation techniques and other samples (e.g.,
experts) had been used for sensitivity analyses. One study
that referred to authors' primary data collection had elic-
ited utilities in a sample of 21 German patients using the
EuroQol instrument. However, only relative reductions in
quality of life expressed as percentage points were docu-
mented. Finally, one analysis reported generation of pri-
mary data using the EQ-5D instrument (VAS and index)
in samples of German patients. However, it is unclear how
the authors estimated index values and which value set
had been applied to calculate quality-adjusted life years.
Measurements were obtained in two treatment arms and
at multiple points in time and the respective sample sizes
could not be determined.
In summary, in only three studies was the original meth-
odology to obtain utilities well documented and compre-
hensible without consulting the original data sources.
With the exception of one study, for which it could not be
determined, no single study relied completely on German
patients' or community health state preferences. Most
concerning, a majority of studies mixed utilities elicited
from various perspectives, nations and weighting
approaches and did not actively disclose these sources of
origin, e.g., by naming the populations in which prefer-
ences had originally been elicited.
Discussion
To the authors' knowledge, this is the first study that pro-
vides a systematic overview of German health economic
evaluative studies. We found that about a third of
included evaluations were published in German-language
and can thus be expected to be missing in international
reviews. In a review of Spanish economic evaluations of
health care covering also earlier years of publication, the
majority of studies (77%) were published in local jour-
nals [17]. As Garcia-Altes we found that those national
analyses that are published in local media are spread over
a high number of journals and can predominantly be
found in journals with a general bio-medical background.
However, our key findings are in concordance with the
results of international analyses of the literature. As oth-
ers, we found that the majority of economic appraisals
concentrate on few disease categories [18]. While these
categories do reflect the current burden of disease in west-
ern societies, some important health areas have gained
only limited attention [19]. For example, musculoskele-
tal, mental and pulmonary diseases are strongly underrep-
resented in the German economic evaluation literature
though they bear a heavy burden that is even likely to
increase in the future. Similarly, the fraction of studies
that examined rehabilitative care is small and has
remained stable over the past 14 years. These results may
not only be explained by authors' research interests or
awareness regarding certain areas of health and health
care, but may also be related to the interests of funding
bodies.
The fact that three quarters of all studies and nearly all
studies evaluating pharmaceuticals that included a fund-
ing statement were industry-sponsored is concerning. The
biases associated with industry-sponsorship have been
acknowledged as being problematic internationally [20-
24]. Bell et al. recently systematically assessed publication
bias in health economic evaluations and found that most
published analyses report favourable incremental cost
effectiveness ratios below 20,000 $/QALY [25]. Studies
funded by industry were more likely to report ratios below
the three analyzed thresholds ((20,000 $/QALY adjusted
odds ratio 2.1, 95% confidence interval 1.3–3.3), 50,000
$/QALY (3.2, 1.8–5.7), and 100,000 $/QALY (3.3, 1.6–
6.8)). Compared to the international literature, the poten-
tial influence of industry-sponsoring in Germany seems
more advanced. In an analysis of evaluations included in
the HEED database that were published between 1992–
2001, Pritchard reports that government and publicly
funded policy making bodies are the most important
source of funds being involved in 40% of studies, fol-
lowed by the pharmaceutical industry at around one third
[26]. As in our study, industry funding is more frequent in
the evaluation of pharmaceuticals but at a considerable
lower level (57% in studies published 1997–2001). This
important role of the pharmaceutical industry in funding
may in part explain why certain health problems or
aspects of care delivery, e.g., rehabilitative care, are under-
represented in health economic studies. The finding that
funding and publication bias is not only inherent in what
is being evaluated but also associated with the results in
terms of favorability of health care interventions calls the
realistic value of health economic evaluations for decision
makers seriously into question.
Our study indicates a systematic trend towards more com-
prehensive methods of evaluation, study perspectives and
study designs. Though this result is encouraging, it has to
be interpreted cautiously. "Comprehensiveness" is not in
itself an exclusive goal and must be accompanied by
methodological rigor in study design, model building,
data collection and other aspects. However, as a limitation
of our study, we extracted data on study characteristics
and did not explicitly assess the quality of studies, e.g., by
approving methods to calculate costs. For example, the
observed increase in clear statements regarding study per-BMC Health Services Research 2007, 7:7 http://www.biomedcentral.com/1472-6963/7/7
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spective can clearly be regarded a development towards
quality of reporting. However, we did not qualitatively ver-
ify whether authors' statements regarding study perspec-
tive were justified. And even in case the labeling of
perspective was justified, this does not necessarily imply
that the chosen perspective itself was appropriate to the
study question.
Regarding key aspects of methodology reporting in health
economic studies, our study also confirms the findings of
Neumann et al. who analyzed adherence to recom-
mended reporting practice in English-language cost-utility
studies published between 1976–1997 and 1998–2001
[1]. As Neumann et al., we observed an increase in
authors' presentation of study perspective over the years.
The fraction of studies that clearly report study perspective
in German analyses published 1999–2004 (62%) is still
considerably lower than in English-language interna-
tional cost-utility analyses published 1998–2001 (73%),
but much higher than the figure that has been reported for
Spanish economic evaluations published 1969–1999
(27%) [17]. Also in concordance with Neumann et al., the
frequency of statements of funding source disclosure in
analyses pertaining to Germany remained stable over the
years.
As reported for the international literature, there is exten-
sive variation in the methodology used for health meas-
urement and preference elicitation in German cost-utility
studies [1,27-29]. Cost-utility-analysis is a methodologi-
cal challenge and the techniques for utility elicitation and
calculation of QALYs can be demanding and complex.
Appropriate study design and reporting of methodology is
therefore crucial, but has been questioned in reviews of
the international literature [30]. Two key aspects can be
concluded from our analysis: First, due to the diversity in
methodology, quality-adjusted life years calculated in dif-
ferent studies are not comparable and compatible with
each other. Second, the vast majority of studies cannot be
termed as assessing health benefits from German patients'
or the German population perspective. This is problem-
atic since intercultural differences in health state prefer-
ences have been observed [31-34]. For example, Greiner et
al. recently investigated differences in time-trade off
(TTO) values for EuroQol health states between the Ger-
man general population and the British "social tariff"
published by Dolan et al. [35,36]. The authors report that
German and British TTO values were significantly differ-
ent for 30 out of 35 health states with the German values
being systematically higher than the UK values. Most con-
cerning, instead of basing the calculation of QALYs con-
sistently on utilities that were obtained in a single
European neighbor population as response to a lack of
primary German data, many analyses included in our
review mixed multiple sources. It can only be hoped for
that recent efforts to estimate European and German "tar-
iffs" will increase consistency in QALY calculations in the
future [37,38]. Recent analyses of the international cost-
utility literature suggest a trend towards the increased use
of generic health status instruments and the elicitation of
preferences in community samples [39]. Besides these
considerations relating to study design itself, the adher-
ence to recommended reporting practices remains a seri-
ous problem. As Richardson and Manca, who undertook
a review of cost-utility-studies conducted alongside rand-
omized clinical trials, we observed an alarming flaw in the
reporting of key methodological aspects in cost-utility-
studies [10]. Gerald et al. report in a review of interna-
tional cost-utility analyses published in 1996 that in
nearly 90% of studies, authors had clearly described how
quality-of-life weights were assigned [30]. In contrast to
this quite satisfactory figure, we often had to consult two
and more secondary studies to gain insight into the very
basic question of preference elicitation, namely: Who has
been asked what? to derive utility weights. Due to a lack of
transparency, e.g., through "chain referencing", many of
the outlined deficits cannot easily be discovered by read-
ers, in particular those unfamiliar with health economics.
Given that the majority of studies are published in medi-
cal journals, and a further diffusion into medical subspe-
cialty journals can be expected, responsibility of editors
and peer-reviewers in the process of publishing is there-
fore essential [30,40,41]. Specialized health economic
databases, such as the NHS-EED, OHE-HEED or the
recently established European Network of Health Eco-
nomic Evaluation Databases (EURONHEED) that include
additional, standardized review of study methodology
and data sources may become increasingly important
tools to assess study quality after publication [42,43].
Conclusion
Many of the German-language evaluations included in
our study are likely to be missing in international reviews
and may be systematically different from English-lan-
guage reviews from Germany. Lack of transparency and
adherence to recommended reporting practices constitute
a serious problem in German economic evaluations.
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